Eudaimonia Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Eudaimonia Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$1.01M	Buy	1,045 +131	+14%	+$125K	0.54%	54
2023 Q4	$803K	Buy	914 +11	+1%	+$9.06K	0.52%	60
2023 Q3	$743K	Hold	903	–	–	0.52%	57
2023 Q2	$649K	Buy	903 +24	+3%	+$18.5K	0.44%	70
2023 Q1	$722K	Sell	879 -20	-2%	-$15.1K	0.49%	60
2022 Q4	$649K	Sell	899 -44	-5%	-$32.5K	0.44%	67
2022 Q3	$650K	Sell	943 -167	-15%	-$105K	0.45%	58
2022 Q2	$656K	Sell	1,110 -17	-2%	-$11.1K	0.45%	63
2022 Q1	$787K	Sell	1,127 -327	-22%	-$207K	0.45%	62
2021 Q4	$918K	Buy	+1,454	New	+$894K	0.54%	48

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Eudaimonia Advisors's REGN Position: Q1 2024 in Review

Eudaimonia Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 14% in Q1 2024, buying an estimated $125K and bringing the position to 1,045 shares worth $1.01M. The position accounts for 0.54% of the portfolio, ranked #54.

Eudaimonia Advisors first reported a position in REGN in Q4 2021 and has held it in 10 quarters since. 1,309 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

Eudaimonia Advisors held 1,045 shares of Regeneron Pharmaceuticals worth $1.01M as of Q1 2024.
Eudaimonia Advisors bought 131 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $125K.
Regeneron Pharmaceuticals made up 0.54% of Eudaimonia Advisors's portfolio in Q1 2024, its #54 holding.
Eudaimonia Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
1,309 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Eudaimonia Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.